Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, β-lapachone

Base excision repair (BER) is an essential pathway for pancreatic ductal adenocarcinoma (PDA) survival. Attempts to target this repair pathway have failed due to lack of tumor-selectivity and very limited efficacy. The NAD(P)H:Quinone Oxidoreductase 1 (NQO1) bioactivatable drug, ß-lapachone (ARQ761...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Sci Rep
Главные авторы: Chakrabarti, Gaurab, Silvers, Molly A., Ilcheva, Mariya, Liu, Yuliang, Moore, Zachary R., Luo, Xiuquan, Gao, Jinming, Anderson, Glenda, Liu, Lili, Sarode, Venetia, Gerber, David E., Burma, Sandeep, DeBerardinis, Ralph J., Gerson, Stanton L., Boothman, David A.
Формат: Artigo
Язык:Inglês
Опубликовано: Nature Publishing Group 2015
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4658501/
https://ncbi.nlm.nih.gov/pubmed/26602448
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/srep17066
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы